HealthSI Analysis
mRNA Cancer Vaccine Shows 34% Reduction in Recurrence in Phase 3 Trial
A Phase 3 clinical trial demonstrates that an individualized mRNA cancer vaccine significantly reduces melanoma recurrence when combined with immunotherapy.
Mar 27, 20268 min[B2]